Amicus Therapeutics

Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Philadelphia, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amicus Therapeutics reports robust revenue growth and eyes AT-GAA launch

Amicus Therapeutics showcased strong performance and growth prospects for Galafold and AT-GAA therapy.
The company aims for non-GAAP profitability in 2023, focusing on key strategic priorities and market expansion.
Challenges include profitability targets, regulatory approvals, and managing production costs for new therapies.
Opportunities lie in the anticipated AT-GAA launch, geographic market expansion, and continued revenue growth.

Amicus Therapeutics reports robust Q1 performance and eyes AT-GAA FDA approval

Amicus Therapeutics delivered strong Q1 results, focusing on revenue growth, regulatory milestones, and financial stability. The company's strengths lie in Galafold sales growth, positive patient outcomes with AT-GAA, and market opportunities in Pompe disease treatment. Challenges include scaling up patient numbers and transitioning manufacturing facilities, while opportunities exist in market expansion and physician engagement.

Amicus Therapeutics excels in Q2, eyes global expansion and profitability

Amicus Therapeutics demonstrates strong financial growth, focusing on expanding market presence and achieving non-GAAP profitability. The company's performance with Galafold and progress on regulatory filings position it well for future success, despite facing challenges in patient transitions and leadership changes.

Amicus Therapeutics reports robust Q3 earnings and growth opportunities

Amicus Therapeutics delivered strong financial results in Q3 2023, with revenue growth and profitability on track, supported by strategic investments and market expansion efforts.
The company's focus on patient-centric approaches, physician engagement, and global market penetration positions it well for future growth and success.
While facing challenges in gene therapy programs and revenue dynamics, Amicus is actively addressing these issues and leveraging opportunities in expanding markets and innovative therapies.
Overall, Amicus Therapeutics remains well-positioned in the biopharmaceutical industry, with a strong foundation for continued growth and impact in treating rare diseases.

Amicus Therapeutics reports strong Q4 earnings and growth opportunities

Amicus Therapeutics delivered strong financial results in Q4 2023, aiming for sustained growth and profitability in 2024 through strategic priorities and successful product launches.
The company faces challenges in forecasting seasonal trends and expanding payer coverage, yet opportunities lie in maximizing patient therapy, leveraging AI advancements, and broadening market reach.
With a focus on rare disease treatments and market penetration, Amicus is poised for growth and intervention strategies to address patient variability and drive revenue in 2024.

Amicus Therapeutics reports strong Q1 performance and growth opportunities

Amicus Therapeutics delivered strong Q1 2024 results, driven by Galafold's performance and a focus on expanding patient numbers for Pombiliti and Opfolda.
While facing challenges such as increased operating expenses and potential manufacturing issues, the company remains confident in its growth trajectory and supply capabilities.
Opportunities lie in revenue expansion, leveraging positive feedback for Pombiliti and Opfolda, and enhancing real-world evidence generation through registries.
Efforts to streamline treatment processes and establish new standards of care position Amicus for continued growth and impact in the rare disease space.

Amicus Therapeutics (FOLD) reports robust Q3 earnings and growth strategies

Amicus Therapeutics (FOLD) delivered strong financial performance in Q3 2024, driven by robust Galafold revenue and strategic focus on patient access.
While facing competitive pressures and regulatory challenges, the company aims to sustain growth through pipeline development and expense management.
Raising financial guidance and exploring accelerated approval opportunities position Amicus for continued success in the genetic medicine market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Princeton, NJ.

PRINCETON, N.J., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that three posters highlighting its development program for Pompe disease will be included at the 29th Annual Congress of the World Muscle Society being held October 8-12, 2024 in Prague, Czechia.

Amicus Therapeutics Announces Participation at the World Muscle Society Annual Congress 2024

Amicus Therapeutics is making steady progress towards promised profitability, driven by the continued growth of Galafold and the launch of Pombiliti+Opfolda. The "beat-and-raise" guidance profile is missing this year and could partially explain the lack of the year-to-date share price momentum. Pombiliti+Opfolda's launch is progressing well, with patients switching from both Nexviazyme and Lumizyme.

'Boring' Amicus Therapeutics Is Making Progress

Dynavax Technologies

GlaxoSmithKline

Intellia Therapeutics

SPDR S&P Biotech ETF

Small-cap biotech stocks have struggled over the past five years, but lower interest rates may boost sentiment and M&A activity, benefiting the sector. One way I have kept my biotech portfolio churning out profits is by embracing using covered call orders to establish positions in small-cap biotech names. Many of these have become consistent profitable “rinse, wash and repeat” trades over the years.

3 'Repeatable' Biotech Trades

PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law LLC announces that it is investigating Amicus Therapeutics, Inc. (NASDAQ: FOLD) (“Amicus”) on behalf of the company's shareholders. Since December 2023, shares of Amicus have declined in value from a trading price of $14.50 per share to a current trading price of approximately $11.00 per share, a decline of nearly 25% in value. The investigation seeks to determine whether Amicus and/or the company's officers and directors violated the securities laws o.

Kaskela Law LLC Announces Shareholder Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Investors to Contact the Firm

PRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in September.

UPDATE -- Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024

Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024

Amicus' (FOLD) lead drug, Galafold, is witnessing solid sales uptake so far. The approval for Pombiliti + Opfolda also aids sales.

Amicus (FOLD) Banks on Galafold, High Dependence a Concern

Amicus Therapeutics focuses on rare diseases like Fabry and Pompe, with Galafold and Pombiliti as main value drivers. Galafold is the only oral treatment for Fabry disease, stabilizing the alpha-Gal A enzyme and capturing significant market share. Pombiliti, combined with Opfolda, treats late-onset Pompe disease, showing strong adoption and receiving multiple awards for its efficacy.

Amicus Therapeutics: A Compelling Investment In The Rare Disease Biotech Sector

Alto Neuroscience Inc

Atlas Lithium Inc

Krispy Kreme

ARS Pharmaceuticals Inc

Are you looking for low-cost stocks to add to your portfolio?

5 Stocks Under $10 Growing 50% Or More

Amicus (FOLD) rises 13% as it reports second-quarter 2024 results, wherein both earnings and sales beat the Zacks Consensus Estimate. The company updates its financial guidance for 2024.

Amicus (FOLD) Up as Q2 Earnings & Sales Top, '24 View Updated

Amicus Therapeutics, Inc. (NASDAQ:FOLD ) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET Company Participants Andrew Faughnan - Vice President, Investor Relations Bradley Campbell - President and CEO Sebastien Martel - Chief Business Officer Dr. Jeff Castelli - Chief Development Officer Simon Harford - Chief Financial Officer Dr. Mitchell Goldman - Chief Medical Officer Ellen Rosenberg - Chief Legal Officer Conference Call Participants Tazeen Ahmad - BofA Securities Ellie Merle - UBS Anupam Rama - JPM Ritu Baral - TD Cowen Michael Riad - Morgan Stanley Dae Gon Ha - Stifel Shrunatra Mishra - Goldman Sachs Rick Miller - Cantor Fitzgerald Operator Good morning, ladies and gentlemen. And welcome to the Amicus Therapeutics Second Quarter 2024 Financial Results Conference Call and Webcast.

Amicus Therapeutics, Inc. (FOLD) Q2 2024 Earnings Call Transcript

The headline numbers for Amicus Therapeutics (FOLD) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Amicus Therapeutics (FOLD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Amicus Therapeutics (FOLD) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to loss of $0.15 per share a year ago.

Amicus Therapeutics (FOLD) Q2 Earnings and Revenues Top Estimates

Q2 2024 Total Revenue of $126.7M, a 34% Increase Year-over-Year Galafold ® Q2 Revenue of $110.8M, up 17% Year-over-Year Pombiliti ® + Opfolda ® Q2 Revenue of $15.9M, up 44% from Q1 2024 Raising 2024 Total Revenue Growth Guidance to 26%-31% at CER  and 2024 Galafold Growth Guidance to 14%-18% at CER Narrowing non-GAAP Operating Expense Guidance to $345M to $360M Non-GAAP Profitability Achieved in Q2 and H1 2024 with Acceleration Expected in H2 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J.

Amicus Therapeutics Announces Second Quarter 2024 Financial Results and Corporate Updates

Washington, D.C., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Today, the U.S. Court of Appeals for the Federal Circuit reversed a decision by the U.S. Court of Federal Claims that dismissed the Darby Development Company v.

In NCLA Amicus Win, Federal Circuit Revives Lawsuit Against CDC's Illegal Eviction Moratorium

People of the State of New York, By State Attorney General Letitia James, against Donald J. Trump, et al. People of the State of New York, By State Attorney General Letitia James, against Donald J. Trump, et al.

NCLA Amicus Brief in NY Case Against Trump Explains Why NY's Executive Law Violates Free Speech

Washington, D.C., July 24, 2024 (GLOBE NEWSWIRE) -- Today, the en banc U.S. Court of Appeals for the Fifth Circuit ruled in Consumers' Research v.

In NCLA Amicus Win, Fifth Circuit Rules Against FCC's Unlawful Control of Universal Service Fund

Corner Post, Inc. v. Board of Governors of the Federal Reserve System Corner Post, Inc. v. Board of Governors of the Federal Reserve System

In NCLA Amicus Win, Supreme Court Upholds Small Business's Right to Judicial Review

Securities and Exchange Commission v. George R. Jarkesy, Jr. and Patriot28, L.L.C. Securities and Exchange Commission v. George R. Jarkesy, Jr. and Patriot28, L.L.C.

In NCLA Amicus Win, Supreme Court Restores Americans' Rights to Trial by Jury

State of Texas; State of Mississippi; State of Louisiana v. Janet Yellen, Richard K. Delmar, U.S. Department of the Treasury, United States of America State of Texas; State of Mississippi; State of Louisiana v. Janet Yellen, Richard K. Delmar, U.S. Department of the Treasury, United States of America

In NCLA Amicus Win, Fifth Circuit Upholds Permanent Block on Treasury's Illegal State Tax Cut Ban

Starbucks Corporation v. M. Kathleen McKinney, Regional Director of Region 15 of the NLRB Starbucks Corporation v. M. Kathleen McKinney, Regional Director of Region 15 of the NLRB

In NCLA Amicus Win, Supreme Court Overturns NLRB-Specific Preliminary Injunction Standard

Scott Johnson, Harlene Hoyt, Covey Find Kennel, LLC v. Justin Smith, D.V.M., in his official capacity as Animal Health Commissioner at the Kansas Department of Agriculture Scott Johnson, Harlene Hoyt, Covey Find Kennel, LLC v. Justin Smith, D.V.M., in his official capacity as Animal Health Commissioner at the Kansas Department of Agriculture

In NCLA Amicus Win, Tenth Circuit Clears Path to Toppling Intrusive Dog Kennel Inspection Regime

National Association of Private Fund Managers, et al. v. Securities and Exchange Commission National Association of Private Fund Managers, et al. v. Securities and Exchange Commission

In NCLA Amicus Win, Fifth Circuit Topples SEC's Unlawful Effort to Regulate Private Funds

PRINCETON, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami, FL on Tuesday, June 11, 2024, at 4:00 p.m. E.T.

Amicus Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

Aurinia Pharmaceuticals

Voyager Therapeutics

Today, we take a look at three promising biotech names that currently trade under $10 a share. Two of these are quickly moving towards profitability, and the other is cash rich and has several partnerships with large pharma companies. We profile all three of these names with favorable risk/reward profiles in the paragraphs below.

News for Amicus Therapeutics Stock (FOLD)